P yoderma gangrenosum (PG) has multiple underlying disease associations, including inflammatory bowel disease (IBD), rheumatoid arthritis, monoclonal gammopathy, vasculitis, streptococcal infections, multiple myeloma, and acute myelogenous leukemia. [1] [2] [3] [4] [5] [6] [7] [8] Whether the underlying comorbidities affect the prognosis or treatment course is unclear. Therefore, the primary objective was to evaluate whether survival in PG is influenced by comorbidity.
Although it was long thought that debridement and grafting are strictly contraindicated, 3, 9 there is some evidence to support skin grafting and gentle debridement once the inflammation is quiescent. 1, 10 Secondary objectives included the determination of whether skin biopsies and procedural techniques such as debridement or grafting are associated with improvements in mortality, hospital length of stay, and hospital costs.
METHODS

Patient database
The study utilized deidentified data and was exempt from the review by the institutional review board of The Ohio State University Wexner Medical Center. Variables of interest were queried from the National Inpatient Sample from 2002 to 2011. The National Inpatient Sample is maintained as part of the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality. 11 It is the largest all-payer inpatient care database in the United States and approximates a 20% stratified sample of nonfederal, acute care hospitals encompassing more than 8 million discharges per year. Each discharge entry includes demographic features of the patient, hospital characteristics, primary and secondary diagnoses, inhospital mortality, hospital cost, and length of stay.
Study population
The study population consisted of all discharged adult patients older than 17 years who had been hospitalized with PG. This diagnosis was selected by using the International Classification of Diseases, Ninth Revision, Clinical Modification codes 686.01 as a primary or secondary diagnosis during the hospitalization. Comorbidities of interest were defined as IBD, inflammatory arthritis (IA), small vessel vasculitis, and leukemia and gammopathies (classified as hematologic dyscrasia). We chose to include small vessel vasculitis as an associated condition for PG on the basis of case reports and experience, particularly given that IgA paraproteinemias may link both morphologies and that lymphocytic vasculitis can be a diagnostic criterion. They were subjected to an algorithm in that order for attribution to PG (Supplemental Table I Table  I ). Typical demographic patient variables were included, and comorbidity was assessed using the Elixhauser score, which is a validated instrument for assessing inpatient data for patient outcomes from a set of 30 comorbid conditions. 12, 13 The comorbidity score was dichotomized as less than 3 versus 3 or more comorbidities. Hospital procedure volume was categorized as high for those at or above the 75th percentile for skin biopsies, low for those between 1% and 74%, and none for those that billed for 0 skin biopsies during the years analyzed.
Statistical analysis
SAS software (version 9.4, SAS Institute, Cary, NC) was used to perform all analyses, using appropriate survey estimation commands and strata weights. Sample data for continuous variables were stated as means with standard deviations. Categoric variables were tested for statistical significance with x 2 tests, whereas differences in continuous variables were analyzed with t tests. Statistical significance was defined by a P value less than .05. Linear regression was used to evaluate the effect of underlying comorbidities and procedures on length of stay (LOS) and hospital cost, and logistic regression was used to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for in-hospital mortality. Multivariable regression models were developed by using a stepwise methodology in which all the variables in Supplemental There is a need for comprehensive evaluation for risk stratification in patients with pyoderma gangrenosum.
(available at http://www.jaad.org) with the exception of the individual Elixhauser comorbidities were eligible for inclusion and adjusted for variables significantly associated with mortality, LOS, and cost in the models.
RESULTS
Demographics
After exclusion of similar ulcerative conditions, 31,885 hospitalizations for patients with a diagnosis of PG were identified during years the 2002 to 2011. The patients were predominately female, with a mean age of 55 plus or minus 0.31 years. The groups spanned the spectrum of race, insurance type, and hospital region (Supplemental Table II ). Most patients had 2 or fewer Elixhauser comorbidities. The most common underlying disease was IBD, with more than 26% of patient hospitalizations followed by patients with IA, hematologic malignancy and dyscrasia, and small vessel vasculitis, whereas in 61% of patient hospitalizations the patient did not have a coded well-described comorbidity. The incidences of streptococcal infections and intestinal blind loop syndromes were less than 1%. Multiple complications were associated with hospitalizations for PG: a chronic wound in 28%, cellulitis in 27%, and sepsis and systemic inflammatory response syndrome in 7% and 5%, respectively. Stoma complications were noted in 6%. The vast majority of hospitalizations did not have cutaneous procedures documented; however, 12% of hospitalized patients underwent a skin biopsy, 11% had debridement, and 3% had a skin graft. There was a disproportionate amount of PG diagnosed in the top quartile of hospitals for skin biopsies with nearly 60% of the diagnoses. Lastly, 731 patients died in this cohort comprising 2% of the population. The hospitalization outcomes for the entire cohort included a mean hospitalization of 8.15 plus or minus 0.14 days and mean cost of $13,159 plus or minus $300.
Multivariable logistic regression modeling for mortality
The diagnoses of small vessel vasculitis (OR, 6.0; 95% CI, 2.63-13.69) and hematologic dyscrasia (OR, 4.31; 95% CI, 1.78-10.43) and all others (OR, 2.23; 95% CI, 1.21-4.11) in comparison with IBD were associated with increased risk of hospitalized patient mortality, whereas the diagnosis of IA was not. In addition, sepsis (OR, 12.43; 95% CI, 8.65-17.86) and increasing age (OR, 1.04; 95% CI, 1.03-1.05) were associated with patient mortality. In comparison, cellulitis was inversely associated with mortality risk (OR, 0.58; 95% CI, 0.39-0.86) ( Table I) .
Multivariable linear regression modeling for LOS
Patients with high Elixhauser comorbidity scores were associated with longer hospitalizations by 2.14 days (95% CI, 1.51-2.78), as were sepsis by 8.89 days (95% CI, 6.88-10.91), stoma complications by 2.67 days (95% CI, 0.74-4.61), chronic wound codes by 1.76 days (95% CI, 1.11-2.40), and the diagnosis of an underlying small vessel vasculitis by 2.17 days (95% CI, 0.12-4.23) or hematologic dyscrasia by 2.22 days (95% CI, 0.14-4.29) as compared with IBD. When looking at procedures, all were associated with increased length of hospitalization, patients who underwent skin biopsies by 2.87 days (95% CI, 1.82-3.91), debridement by 5.32 days (95% CI, 3.96-6.68), or skin grafts by 7.93 days (95% CI, 4.14-11.72) (Table II) .
Multivariable linear regression modeling for hospital cost
Hospitalizations with higher Elixhauser comorbidity scores were associated with increased hospitalization costs of $4321 (range, $2948-$5694), whereas the comorbidities vasculitis $5981 (range, $67-$11,896) and hematologic dyscrasia $7715 (range, $1775-13,655) also increased the costs, respectively, compared with the costs for IBD reference patients. Hospitalizations involving debridement, skin biopsy, and skin grafting were consistently more expensive. In addition, hospitalization costs were increased with sepsis $22,448 (range, $17,659-$27,237), postsurgical complications $11,463 (range, $2319-$20,608), and patients at centers that were categorized as higheskin biopsy volume $1874 (range, $293-$3454) (Table III) . 
DISCUSSION
Previous studies have demonstrated the high mortality rate in patients with PG ([15% in an 8-year longitudinal study). 1 The present study demonstrates an in-hospital mortality risk of around 2% with significant variation based on comorbidities. It confirms that there is important prognostic value that is lost in the event that a patient is not thoroughly evaluated for a monoclonal gammopathy, myeloma, or leukemia. Interestingly, cellulitis was associated with a decreased mortality risk, but similar associations have been reported in psoriasis hospitalizations. 14 This may indicate that there is a high rate of misdiagnosis or an overstated systemic risk from the coded diagnosis of cellulitis. From the procedure analyses, skin biopsies were performed in a minority of patient hospitalizations; however, many patients may have already carried the diagnosis of PG. In the hospital setting, the skin biopsy was associated with longer hospitalization and higher costs. This may be a surrogate for an initial or more thorough evaluation. Previous studies have also demonstrated the association of skin biopsies with longer hospitalizations. 15 Similarly to skin biopsies, skin grafts and debridement were actually associated with increased lengths of stay and costs without benefits in mortality.
Multiple limitations exist in this current study, including the fact that 60% of patients did not have a classically associated diagnosis by coding. This could represent coding error, unevaluated comorbidities, or even misdiagnosis. The validation of this disease by using cross-sectional data is challenging, but coding of data by general physicians in England has demonstrated a 50% to 75% positive predictive value in the coded diagnosis of PG, and we suspect that our outcomes may be higher with the benefit of more specialists. 7 Further, 68% of patient hospitalizations for PG were within hospitals that were in the top quartile for skin biopsy volume, indicating that most probably had access to dermatologists to make this specialized diagnosis. From the procedural aspect, its value may be understated without being able to follow patients longitudinally. Lastly, we hoped to study rare associations such as pneumonitis and PG, but such complications were so rarely coded that we could not reliably quantify outcomes in this setting.
In conclusion, mortality risk varied substantially among patients with small vessel vasculitis and hematologic malignancy/dyscrasia in comparison with that in patients with IBD and IA. This emphasizes the need for comprehensive diagnostic evaluation. Procedural treatments did not show a benefit in this setting but ought to be studied further by using longitudinal databases.
Supplemental Table I . ICD-9-CM codes used in study methodology for diagnosis of PG, associated comorbidities, and exclusion of similar diagnoses and procedure codes 
